Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
541-560 of 1,307 trials

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Recurrent Low-Grade Serous Ovarian Cancer: Avutometinib and Defactinib Study

We are studying a new combination therapy for patients with recurrent low-grade serous ovarian cancer to see if it helps them live longer and improves their quality of life compared to standard treatments.

Recurrent Low-Grade Serous Ovarian Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Pain Management in Dental Emergencies: Methoxyflurane Study

We are studying whether methoxyflurane can effectively reduce pain and anxiety in adults facing oral emergencies. This trial will help us understand its benefits compared to a placebo.

Dental Pain and Sensation Disorders1-2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsOtolaryngologyPediatrics

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

We are studying whether zanidatamab combined with standard chemotherapy helps patients with advanced HER2-positive biliary tract cancer more than standard chemotherapy alone. This trial aims to evaluate its effectiveness and safety.

Biliary Tract CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Acute Mesenteric Ischemia: Oral Antibiotics Study

We are investigating whether oral antibiotics can help reduce serious complications in patients with acute mesenteric ischemia. This study compares the effects of antibiotics to a placebo to see if they improve patient outcomes.

Acute Mesenteric Ischemia>2 yearsConfirmation phase (III)Standard MedicinesCardiologyGastroenterology

Psoriatic Arthritis: Tapering Immunosuppressive Therapy

We are studying whether reducing immunosuppressive medication helps adults with psoriatic arthritis maintain stable disease activity. The trial also looks at the safety of this approach.

Psoriatic Arthritis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineRheumatology

Noncardiac Surgery: Noradrenaline Infusion Study

We are investigating if noradrenaline infusion is more effective than standard blood pressure management in preventing low blood pressure during noncardiac surgery. This study aims to improve patient safety and outcomes in the operating room.

Low Blood Pressure During Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyOtolaryngology

Ovarian Cancer: SALVOVAR Trial on Chemotherapy Regimens

We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.

Advanced Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart vs. IVIg

We are studying a new treatment called riliprubart to see if it works better than the standard IVIg therapy for people with chronic inflammatory demyelinating polyneuropathy. The trial will evaluate its effects on disability, fatigue, and overall quality of life.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesInternal MedicineNeurology

Lung Cancer: ABP 234 vs. Keytruda

We are evaluating a new treatment for early-stage non-squamous non-small cell lung cancer to see how it compares to Keytruda after surgery and chemotherapy. This study aims to understand if the new drug works similarly in the body.

Early-stage Non-squamous Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)OncologyPulmonology

Renal Lifecycle Trial: Dapagliflozin for Severe Chronic Kidney Disease

We are studying whether dapagliflozin can improve kidney and heart health in patients with severe chronic kidney disease. This includes those on dialysis and kidney transplant recipients.

Healthy Participants>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCardiologyNephrology

Chronic Lymphocytic Leukemia: Acalabrutinib vs. Venetoclax

We are comparing two treatment combinations for newly diagnosed chronic lymphocytic leukemia patients to see which is more effective and safer. We will also look at how these treatments affect patients' quality of life.

Chronic Lymphocytic Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Hyperkalaemia in Children: SZC Treatment Study

We are studying whether the medication SZC can safely normalize potassium levels in children with hyperkalaemia. The trial will also check how well it maintains these levels over time.

High Potassium Levels (Hyperkalemia)6-12 monthsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNephrologyPediatrics

Atherosclerotic Cardiovascular Disease: Obicetrapib and Ezetimibe Study

We are testing a new combination therapy for people with atherosclerotic cardiovascular disease to see how it affects coronary plaque and overall heart health. This study aims to understand its safety and effectiveness compared to a placebo.

Atherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyEndocrinology

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInfectious DiseasesInternal Medicine

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Alport Syndrome: Dapagliflozin for Kidney Health

We are studying whether Dapagliflozin can help slow the progression of kidney disease in adolescents and young adults with Alport syndrome. This trial aims to improve treatment options for those with this condition.

Alport's Syndrome>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineNephrology